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Fabrizio Veglia, PHD,† Cesare Fiorentini, MD,† Carlo M. Cipolla, MD*
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Objectives The purpose of this study was to evaluate the clinical relevance of anthracycline-induced cardiomyopathy
(AC-CMP) and its response to heart failure (HF) therapy.
Background The natural history of AC-CMP, as well as its response to modern HF therapy, remains poorly defined. Hence,
evidence-based recommendations for management of this form of cardiomyopathy are still lacking.
Methods We included in the study 201 consecutive patients with a left ventricular ejection fraction (LVEF) 45% due to
AC-CMP. Enalapril and, when possible, carvedilol were promptly initiated after detection of LVEF impairment.
LVEF was measured at enrollment, every month for the first 3 months, every 3 months during the first 2 follow-
ing years, and every 6 months afterward (mean follow-up 36  27 months). Patients were considered respond-
ers, partial responders, or nonresponders according to complete, partial, or no recovery in LVEF, respectively.
Major adverse cardiac events during follow-up were also evaluated.
Results Eighty-five patients (42%) were responders; 26 patients (13%) were partial responders, and 90 patients (45%)
were nonresponders. The percentage of responders progressively decreased as the time from the end of chemo-
therapy to the start of HF treatment increased; no complete recovery of LVEF was observed after 6 months. Re-
sponders showed a lower rate of cumulative cardiac events than partial and nonresponders (5%, 31%, and 29%,
respectively; p  0.001).
Conclusions In cancer patients developing AC-CMP, LVEF recovery and cardiac event reduction may be achieved when car-
diac dysfunction is detected early and a modern HF treatment is promptly initiated. (J Am Coll Cardiol 2010;
55:213–20) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.03.095(
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phemotherapy-induced cardiotoxicity is a rapidly evolving
rea, as well as one of growing interest, due to the increasing
umber of long-term cancer survivors. The most common
linical presentation of cardiotoxicity is a dose-dependent
ardiomyopathy (CMP) leading to chronic heart failure
HF), frequently occurring after administration of chemo-
herapy including anthracyclines (ACs) (1,2).
Because most studies and registries have not specifically
nalyzed anthracycline-induced cardiomyopathy (AC-
MP) among the several possible causes of chronic HF, its
revalence is not well known. From among the few studies
n which the etiology of HF has been evaluated in detail, a
revalence of 1% of all cases of CMP has been reported
ontinuing Medical Education (CME) is available for this article. From the
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ilan, Milan, Italy. This study was funded by the European Institute of Oncology.(
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ccepted March 10, 2009.3,4). Data from oncology literature, however, indicate that
ore than one-half of all patients exposed to AC will show
ome degree of cardiac dysfunction 10 to 20 years after
hemotherapy, and 5% of them will develop overt HF (5).
s more than 60,000 patients are treated every year with
C in the U.S., the overall incidence of this complication is
robably greatly underestimated (6). The onset of AC-
MP, even asymptomatic, not only negatively impacts the
ardiac outcome of cancer patients (7,8), but also seriously
imits their therapeutic opportunities. Indeed, patients with
oor-prognosis cancer require adjunctive chemotherapy for
isease relapse after a first line of chemotherapy in more
han 30% to 60% of cases within 5 years (9,10), and the
resence of AC-CMP restricts the choice of possible
ncologic treatments to those considered less aggressive
nd, consequently, less effective (1,11–13).
Compared with other more frequent forms of CMP,
C-CMP has been associated with an especially poor
rognosis, with a 2-year mortality rate of up to 60%
3,14,15), and is also believed to be refractory to conven-
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Anthracycline-Induced Cardiomyopathy January 19, 2010:213–20tional therapy. Most data con-
cerning the natural history of this
disease and its treatment, how-
ever, are anecdotal or based on
findings reported in old studies,
in which standard therapy in-
cluded only the use of digoxin
and diuretics (15,16). The re-
sponse to modern HF therapy of
AC-CMP has never been evalu-
ated in clinical trials, and the effec-
tiveness of angiotensin-converting
enzyme inhibitors (ACEIs) and
eta-blocking agents in this particular clinical setting can be
ound in a very few studies that involved small populations.
oreover, data on long-term outcomes of treated and un-
reated patients with AC-CMP are limited. As a consequence,
vidence-based recommendations for the management of can-
er patients with asymptomatic and symptomatic AC-CMP
re still lacking, and no definite guidelines are currently
dopted.
The aim of the present study was to prospectively evaluate
large population of symptomatic and asymptomatic pa-
ients with AC-CMP and to examine their response to
odern medical HF therapy.
ethods
tudy population. This prospective study was conducted
t the European Institute of Oncology, University of Milan,
etween March 1, 2000, and March 1, 2008. Among
atients treated with AC in our own institute, as well as
hose referred to our Cardiology Unit from other oncologic
nstitutes after the detection of cardiotoxicity or for evalu-
tion before new oncologic treatment due to disease relapse,
e considered all consecutive patients with echocardio-
raphic evidence of left ventricular systolic dysfunction,
egardless of the presence of HF symptoms. Patients were
ligible for enrollment if they fulfilled the following inclu-
ion criteria: 1) evidence of left ventricular ejection fraction
LVEF) 45%; and 2) absence of any identifiable cause of
MP other than chemotherapy, excluded by clinical history
nd, in patients with risk factors for coronary artery disease
r electrocardiographic abnormalities, by exercise- or
harmacologic-induced provocative tests, coronary angiogra-
hy, or coronary multislice computed tomography.
All patients younger than 18 years of age, those with
ontraindication to ACEIs or beta-blockers, already in
reatment with these drugs, previously treated with chemo-
herapy schedules not including AC, with severe (stage 4)
enal insufficiency (17), and with an oncologic life expect-
ncy shorter than 12 months were excluded from the study.
he investigation conformed with the principles of the
eclaration of Helsinki; the study was approved by our
nstitutional review board, and all patients provided written
Abbreviations
and Acronyms
AC  anthracycline
ACEI  angiotensin-
converting enzyme inhibitor
CMP  cardiomyopathy
HF  heart failure
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Associationnformed consent for clinical research analysis. ttudy protocol. All study patients underwent physical
xamination, electrocardiogram, and echocardiogram, in-
luding measurement of LVEF (biplane method accord-
ng to modified Simpson’s rule) (18) at time of enroll-
ent; after 1, 2, and 3 months from the beginning of
ardiac therapy; every 3 months during the first 2 years of
bservation; and every 6 months afterward or whenever
equired by the clinical situation. In the case of patients
ho were lost or who died during follow-up, the evalu-
tion performed at the last follow-up check was consid-
red the final measurement.
The primary end point of the study was the LVEF
esponse to HF therapy. During follow-up, patients were
onsidered as responders when LVEF increased up to the
ormal limit of 50%, as partial responders when LVEF
ncreased at least 10 absolute points but did not reach the
imit of 50%, and as nonresponders when LVEF in-
reased fewer than 10 absolute points and did not reach the
imit of 50%.
Secondary end points included the occurrence of major
dverse cardiac events during follow-up. The following
ardiac events were considered: 1) sudden death; 2) death
esulting from a cardiac cause; 3) acute pulmonary edema;
) overt HF requiring hospitalization; 5) life-threatening
rrhythmias requiring treatment; and 6) conduction distur-
ances requiring a permanent pacemaker implantation.
tudy treatment. By protocol, in all patients, enalapril was
he first initiated treatment at a dose of 2.5 to 5 mg/day
according to baseline systemic arterial pressure), once or
wice a day, and gradually up-titrated to 20 mg/day, or to
he maximal-tolerated dose. In patients receiving at least 5
g/day of enalapril, carvedilol was given at an initial dose of
.25 mg/day (3.125 mg twice a day) and progressively
p-titrated to the maximal-tolerated dose or to 50 mg/day.
Additional pharmacologic treatment, including diuretics,
nticoagulants, and antiarrhythmic drugs, was given as needed
t the discretion of the cardiologist responsible for the patient
nd on the basis of current standards of care (19).
tatistical analysis. A sample size of 200 patients allowed
0% statistical power to assess as significant, with alpha
rror of 0.05, and an odds ratio (OR) of 1.6 of the primary
nd point (partial or nonresponse to treatment) for 1 SD
ncrease in any predictor examined.
Continuous variables are presented as mean (SD) and
ere compared among groups by 1-way analysis of variance.
ategorical data are presented as absolute values and per-
entages and were compared using the chi-square test or the
isher exact test, as appropriate. Due to its skewed distri-
ution, the time from the end of chemotherapy to the start
f HF treatment (time-to-HF treatment) was presented as
edian and interquartile range.
Linear regression analysis was used to explore the rela-
ionship between LVEF maximal change during the
ollow-up period and time-to-HF treatment. Time-to-HF
reatment was log transformed before analysis.
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January 19, 2010:213–20 Anthracycline-Induced CardiomyopathyA multivariable logistic regression model with stepwise
election of variables was used to identify independent
redictors of the primary outcome (LVEF recovery). Can-
idate variables were age, sex, cardiovascular risk factors,
umulative AC dose, time-to-HF treatment, radiotherapy,
reatinine clearance, enalapril and carvedilol association,
nd New York Heart Association (NYHA) functional class.
s LVEF at start of HF treatment is strongly associated
ith final LVEF, and as a consequence, to the primary end
oint of the study, it was not considered among the
otential independent predictors. This variable, however,
as forced into the final model in order to confirm the other
elected predictors. Adjusted OR and 95% confidence
ntervals (CIs) were computed.
LVEF recovery was also analyzed as a continuous variable
difference between final and baseline value). In this case,
ultiple linear regression analysis with stepwise selection of
ariables was used to obtain the independent predictors of
he following LVEF changes.
Kaplan-Meier analysis was used to compare the time-to-
vent rate among the 3 groups. A p value 0.05 was consid-
red statistically significant.
All tests were 2-sided, and all analyses were performed
sing SAS software package (version 9.13, SAS Institute,
ary, North Carolina).
esults
wo hundred fifteen consecutive patients were initially en-
olled. Fourteen patients were excluded from the analysis
ecause of associated coronary artery disease (n 3), early (2
onths) death from oncologic disease (n  2), or lost to
ollow-up (n 9). A total of 201 patients (mean age 53 12
ears; 149 women) were included in the study. Baseline
before AC therapy) LVEF was available in 148 (74%)
atients. On presentation, 148 patients (74%) were in
YHA functional class I or II and 53 (26%) were in class III
r IV. In 72 patients (36%), only enalapril was given (mean
ose 11  7 mg/day). In these patients, reasons for lack of
he addition of carvedilol were symptomatic hypotension
n  40), critical bradycardia (n  6), and severe asthenia
n  26). The remaining 129 patients received the
ombination of enalapril (mean dose 12  6 mg/day) and
arvedilol (mean dose 14  7 mg/day). In 4 patients who
eferred with cough, enalapril dosage was decreased with
ymptom resolution.
The median time-to-HF treatment was 4 months (inter-
uartile range 2 to 14 months). The mean follow-up duration
fter start of HF treatment was 36  27 months (range 12 to
6 months). During this period, 85 patients (42%) normalized
heir LVEF and were considered responders; 26 patients (13%)
ere partial responders, and 90 patients (45%) were nonre-
ponders. Neither new electrocardiographic Q waves nor other
bnormalities were observed, nor did acute coronary syndromes
ccur during the follow-up. One hundred seven (53%) patients fiere given additional chemotherapy, and 62 (31%) died from
ncologic disease during the study period.
The clinical characteristics, the HF therapy, and the
ncologic treatment before enrollment of the 3 study groups
re shown in Table 1 (20,21). There were not significant
ifferences in terms of baseline characteristics, type of
ncologic treatment received, or total dose of AC. Respond-
rs had a significantly shorter time-to-HF treatment and
ere more likely to tolerate the combination of enalapril and
arvedilol. In these patients, complete reversal of LVEF
mpairment was observed at 7  4 months from the start of
F therapy. The percentage of responders progressively
ecreased as the time-to-HF treatment increased. Notably,
n no patient was complete LVEF recovery observed after a
ime-to-HF treatment longer than 6 months (Fig. 1).
Patients with either partial or no LVEF increase after
reatment experienced a more complicated clinical course, with
higher rate of cumulative cardiac events, including death,
ccurring more frequently in these 2 groups (Table 2). The
umulative cardiac event rate as a function of the follow-up
ime based on Kaplan-Meier estimates in the 3 groups is
hown in Figure 2.
Figure 3 shows LVEF changes in response to HF therapy
n several subsets of patients, as defined by age, sex,
ymptom severity, type of HF therapy, time-to-HF treat-
ent, and cumulative AC dose.
At multivariate analysis (logistic regression with stepwise
election of variables in the model, including age, sex,
ardiovascular risk factors, cumulative AC dose, time-
o-HF treatment, radiotherapy, creatinine clearance, enala-
ril and carvedilol combination, and NYHA functional
lass), time-to-HF treatment and NYHA functional class
ere selected as the only independent predictors of lack of
omplete LVEF recovery (OR: 3.9; 95% CI: 2.7 to 5.7;
 0.0001 for each doubling in time-to-HF treatment;
R: 8.7; 95% CI: 3.0 to 25; p  0.0001 for NYHA
unctional class III or IV). When pre-HF treatment LVEF
as forced into the final model, time-to-HF treatment and
YHA functional class were still confirmed as significant
nd independent predictors. When patients with both a
ime-to-HF treatment 6 months and an NYHA func-
ional class I or II were considered, positive predictive value
or complete LVEF recovery was 84%, and negative pre-
ictive value was 87% (sensitivity 82%; specificity 89%).
In the entire population, the LVEF maximal change
uring follow-up, considered a continuous variable, was
nversely related to log-time-to-HF treatment (Fig. 4).
iscussion
he major finding of the present study is that, in patients
ith AC-CMP, an early treatment allows for complete
ecovery of LVEF and positively impacts cardiac outcome.
Historically, AC-CMP was believed to be refractory to
onventional therapy. This opinion, however, was based on
ndings reported in old studies in which standard therapy
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‡
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Anthracycline-Induced Cardiomyopathy January 19, 2010:213–20linical Characteristics of the 3 Study GroupsTable 1 Clinical Characteristics of the 3 Study Groups
Responders
(n  85)
Partial Responders
(n  26)
Nonresponders
(n  90) p Value
Age, yrs 52 12 53 10 54 13 0.36
Women 65 (76) 21 (81) 63 (70) 0.48*
Hypertension 27 (32) 6 (23) 24 (27) 0.96
Diabetes 5 (6) 2 (8) 10 (11) 0.49*
Hypercholesterolemia 6 (7) 3 (11) 10 (11) 0.59*
Current or past smokers 32 (38) 10 (38) 33 (37) 0.98
Family history of CAD 11 (13) 5 (19) 10 (11) 0.53*
NYHA functional class III or IV 11 (13) 18 (69) 24 (27) 0.001
LVEF before AC therapy, % 62 4 60 4 60 4 0.16
LVEF before HF therapy, % 41 5 28 4 38 7 0.001
LVEF at the end of the study, % 55 3 44 4 38 8 0.001
Mitral regurgitation grade 3 or 4 4 (5) 1 (4) 8 (9) 0.56*
Creatinine clearance† (ml/min) 110 45 94 26 95 42 0.05
Oncologic disease 0.26‡
Acute lymphatic leukemia 1 (1) 1 (4) 5 (6)
Breast cancer 52 (61) 16 (62) 39 (43)
Hodgkin’s disease 3 (3) 0 (0) 8 (9)
Non-Hodgkin’s lymphoma 16 (19) 4 (15) 21 (23)
Other tumors 14 (16) 4 (15) 17 (19)
Time-to-HF treatment (months) 2 (1–3) 4 (2–6) 17 (8–36) 0.001
HF therapy
Enalapril and carvedilol 67 (78) 13 (50) 49 (54) 0.001
Diuretics 21 (25) 18 (69) 45 (50) 0.001
Amiodarone 0 (0) 4 (9) 8 (9) 0.001*
Anticoagulants 1 (1) 2 (8) 5 (6) 0.15*
Antineoplastic treatment
Anthracyclines§
Doxorubicin 37 (44) 11 (42) 40 (44) 0.98
Epirubicin 36 (42) 10 (38) 31 (34) 0.56
Daunorubicin 1 (1) 0 (0) 2 (2) 1.00*
Doxorubicin  epirubicin 2 (2) 1 (4) 4 (4) 0.66*
Doxorubicin  epirubicin  idarubicin 0 (0) 0 (0) 2 (2) 0.61*
Doxorubicin  idarubicin 6 (7) 2 (8) 3 (3) 0.42*
Doxorubicin  idarubicin  mitoxantrone 0 (0) 0 (0) 2 (2) 0.61*
Doxorubicin  mitoxantrone 1 (1) 1 (4) 6 (7) 0.18*
Daunorubicin  idarubicin 1 (1) 1 (4) 0 (0) 0.12*
Liposomal doxorubicin 1 (1) 0 (0) 0 (0) 0.55*
Taxanes in addition to anthracyclines 25 (29) 4 (15) 13 (14) 0.04*
Monoclonal antibodies in addition to anthracyclines
Trastuzumab 0 (0) 0 (0) 0 (0) 1.00*
Bevacizumab 0 (0) 0 (0) 0 (0) 1.00*
Rituximab 5 (6) 4 (15) 10 (11) 0.25*
Cumulative anthracycline dose (mg/mq) 301 124 341 130 333 150 0.24
Cardioprotective agents
Dexrazoxane 1 (1) 0 (0) 0 (0) 0.55*
Mediastinum RT¶ 6 (7) 1 (4) 12 (13) 0.28*
Chest-wall RT (left)# 24 (28) 9 (34) 15 (17) 0.07
Mean follow-up duration (months) 34 26 46 30 36 27 0.10
Additional CT during follow-up 48 (56) 13 (50) 46 (51) 0.73
Oncologic death during follow-up 23 (27) 9 (35) 30 (33) 0.60
ata are expressed as n (%) or mean  SD except for time to HF treatment, which is expressed as median (interquartile range). *By Fisher exact test. †Estimated by Cockcroft-Gault formula (20).
Cumulative p value. §ACs were given in all cases as a slow intravenous bolus over 15 to 30 min. Cumulative AC dose was calculated by converting different AC agents in terms of doxorubicin equivalents
21). ¶Total dose 30 Gy. #Total dose 60 Gy.
AC  anthracyclines; CAD  coronary heart disease; CT  chemotherapy; HF  heart failure; LVEF  left ventricular ejection fraction; NYHA  New York Heart Association; RT  radiotherapy.
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January 19, 2010:213–20 Anthracycline-Induced Cardiomyopathyncluded only the use of digoxin and diuretics (16,22,23) or
n studies with very small sample sizes (14,24–30). The
esponse to modern HF therapy of patients with AC-CMP
as never been fully investigated, because typically, these
atients have been excluded from large randomized trials
valuating the effectiveness of novel HF therapies.
Due to the different etiology and age distribution of this
ind of CMP, when compared with the more frequent
schemic or idiopathic CMPs, there is some concern regard-
ng whether the use of ACEI and beta-blocking agents,
ecommended by the international cardiologic guidelines,
an be directly transferred to this particular clinical setting
ith similar long-term benefits (6). Moreover, one of the
ore challenging features of cardiac dysfunction due to AC
s the asymptomatic nature of the disease (5). For this
eason, many authors have suggested only screening pro-
rams to look for overt HF, and current management of
C-CMP mainly focuses on treatment of symptomatic
atients (27,29). A crucial issue is whether or not, and
ventually how, to treat patients still asymptomatic, in
hom left ventricular dysfunction is detected on routine
creening examinations. To date, there is no consensus
bout what (if anything) can be done to curtail the progres-
ion of AC-CMP (6). As a consequence, evidence-based
ecommendations for management of cancer patients with
symptomatic and symptomatic AC-CMP are still lacking.
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Figure 1
Percentage of Responders According to the
Time Elapsed From AC Administration and
Start of HF Therapy
AC  anthracyclines; HF  heart failure.
ardiac Events in the 3 Study GroupsTable 2 Cardiac Events in the 3 Study Groups
Total
(n  201)
Sudden death 1 (0.5%)
Cardiac death 3 (1.5%)
Acute pulmonary edema 2 (1%)
Heart failure requiring hospitalization 7 (3.5%)
Life-threatening arrhythmias 20 (10%)
Conduction disturbances requiring pacemaker implantation 5 (2.5%)
Cumulative events 38 (19%)or each patient, only the first event was considered. *p  0.001.redictors of LVEF recovery. In our study, a short time-
o-HF treatment and a low NYHA functional class were
elected as the only independent predictors of LVEF
ecovery. In particular, time-to-HF treatment represents the
ajor critical variable in this population. Indeed, an inverse
elationship clearly exists between the time elapsed from the
nd of chemotherapy and the beginning of HF therapy and
mprovement in LVEF. We found an approximately 4-fold
ecrease in the chance of complete recovery from cardiac
ysfunction for each doubling in time-to-HF treatment.
ctually, the percentage of patients with a complete LVEF
ecovery, among those treated within 2 months after the end
f CT, is 64%; after this time limit, however, this percent-
ge gradually decreases, and no complete LVEF recovery is
bserved after 6 months (Fig. 1). After 12 months, the
ossibility of obtaining at least a partial LVEF improvement
s completely exhausted. Moreover, baseline NYHA func-
ional class III or IV is a strong predictor of lack of response
o HF therapy. Therefore, cardiac monitoring exclusively
ased on symptoms evaluation may miss the opportunity to
etect cardiotoxicity early and in a still-reversible stage.
Considering these 2 independent variables together (a
ime-to-HF treatment 6 months and an NYHA func-
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Figure 2 Cumulative Cardiac Event
Rate During the Study Follow-Up
2-year Kaplan-Meier analysis for major adverse
cardiac events in the 3 study groups. p  0.0003 (log-rank test).
Responders
(n  85)
Partial Responders
(n  26)
Nonresponders
(n  90)
0 (0%) 0 (0%) 1 (1%)
0 (0%) 0 (0%) 3 (3%)
0 (0%) 1 (2%) 1 (1%)
0 (0%) 1 (2%) 6 (7%)
4 (3%) 4 (15%) 12 (13%)
0 (0%) 2 (8%) 3 (3%)
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Anthracycline-Induced Cardiomyopathy January 19, 2010:213–20ional class I or II) as indicators for LVEF recovery at the
ime of first detection of AC-CMP, we can accurately
redict response to therapy, as well as the risk of future
ardiac events. This information permits clinicians to better
tratify the overall (oncologic and cardiac) risk of cancer
atients developing cardiotoxicity and to plan future strat-
gies in case of cancer relapse and need for additional
hemotherapy. Notably, in our study, most patients with
ancer relapse during follow-up were not treated with AC
particularly doxorubicin, the most cardiotoxic AC) because
f cardiac dysfunction.
The importance of an early diagnosis and start of treat-
ent for achieving a reversion of AC-CMP is in agreement
ith our previous studies, which show that, in AC-treated
atients with myocardial cell injury disclosed by a rise of
roponin I, enalapril prevents LVEF decrease as well as the
ccurrence of associated cardiac events (31). This empha-
izes the crucial importance of an early detection of cardio-
oxicity in order to effectively prevent AC-CMP or to treat
atients in a phase in which the disease is still reversible.
Responders more frequently tolerated a combination of
nalapril and carvedilol. This underlines the fact that an
ptimized approach based on the association of these 2 drugs
hould always be considered, and attempted, in all AC-CMP
atients. In our study, by protocol, enalapril was the first
nitiated treatment in accordance with the international rec-
30
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Figure 3 LVEF Changes in Several Subsets of Patients
Left ventricular ejection fraction (LVEF) before (baseline) and after (final) heart failu
anthracycline (AC) dose, patients were stratified according to the median value. p
BB  beta-blocker; M  men; NYHA  New York Heart Association; W  women.mmendations for chronic HF therapy at the time the studyas designed (32) and with the further evidence of the crucial
ole of the cardiac tissue renin-angiotensin system in the
athogenesis of AC-CMP (33,34). However, given the pecu-
iar characteristics of AC-CMP, often characterized by inap-
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Figure 4 Correlation Between LVEF
Changes and Time-to-HF Treatment
Relationship between maximal left ventricular ejection fraction changes (LVEF)
during the follow-up period and log time elapsed from chemotherapy and start
of treatment (time-to-heart failure [HF] treatment).II-IV
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nderlying oncologic disease and treatment (30), we cannot
xclude that a first treatment with carvedilol could have
rovided a greater benefit in terms of LVEF recovery and
eduction of cardiac events.
omparison with previous studies. At present, it is very
ifficult to obtain evidence-based indications for the treat-
ent of AC-CMP from the existing literature. Pooling all
he data together, an overall adult population of 108 patients
an be derived from a total of 11 previous publications (6
ase reports and 5 clinical studies) (14,16,22–30). Only 2 of
hem, however, were prospective studies (24,27), and only 3
ad pre-defined end points (24,27,29). In all patients,
reatment was started only when symptoms of HF occurred.
orty-six patients (43%) were treated with digitalis and
iuretics, and 32 patients (30%) were treated with different
CEIs (enalapril in most cases); among them, only 13
atients received ACEIs as a first treatment. Finally, only 5
atients (5%) were treated with beta-blockers alone (carve-
ilol in most cases), and only 25 patients (23%) received a
ombination of both these classes of drugs. Therefore, no
lear evidence can be obtained from these findings in terms
f defining the best therapeutic strategy for this CMP.
onversely, the large population we considered, the pro-
pective design, the homogeneous treatment schedule, the
ong-term follow-up, and the pre-defined functional and
linical end points all represent clear strengths in our study.
In long-term pediatric cancer survivors with AC-CMP,
reatment with enalapril slowed the progression of cardiac
ysfunction, but did not reverse it (6,35). On the basis of the
esults of these 2 studies, the routine use of ACEIs is not
ecommended at present (36). In these 2 studies, however,
he mean time-to-HF treatment was 6.9 and 7.2 years,
espectively. Considering our findings, it is not surprising
hat such an approach was doomed to fail.
Although preventing AC-induced cardiotoxicity while
reating the malignancy remains the ultimate goal of ther-
py, cardiac function should also be monitored in patients
eceiving potentially cardiotoxic chemotherapy in order to
etect early cardiac abnormalities while they are still revers-
ble. Indeed, the American College of Cardiology and the
merican Heart Association recommend routine echocar-
iography at baseline and recurrent re-evaluation (37).
owever, in “real world” practice, this recommendation is
ften disregarded in asymptomatic patients and in those
ecovered from the oncologic disease. The results of our
tudy highlight the fact that an early treatment is particu-
arly critical in asymptomatic patients. Indeed, most re-
ponders were either asymptomatic or had a low NYHA
unctional class at the time HF therapy was initiated.
ncologists and cardiologists should plan these assessments
ointly, as therapy decisions involving the same patients may
otentially mean exchanging one fatal disease for another.
tudy limitations. First, we included a population admit-
ed to a single center. Second, the possibility that clinical
ariables or complications other than chemotherapy mayave influenced the response to HF therapy cannot be
xcluded. Similarly, we cannot completely exclude the
ossibility that diverse forms of AC-CMP (i.e., acute,
ubacute, or late) may have a different response to HF
herapy, or that, as the natural history of AC-CMP has not
een well elucidated yet, spontaneous recovery in LVEF
ay occur in some patients. Third, the poor response to
reatment of patients with more symptomatic HF (NYHA
unctional class III or IV) was possibly influenced by the
efinition of responders we used. Indeed, although they less
requently reached the criteria for complete recovery of
VEF, their absolute increase in LVEF was greater than
hat of asymptomatic patients (Fig. 3). Therefore, a high
aseline NYHA functional class should not preclude treat-
ent of these patients with an effective HF therapy,
articularly when the CMP is detected in an early phase
fter chemotherapy. Nevertheless, in our study, the inci-
ence of cardiac events was similar in partial and nonre-
ponder patients, despite a significant increase in LVEF in
he former group. This highlights the critical importance of
ormalizing, and not just improving, LVEF in this setting
n order to positively impact clinical outcome. Finally, it is
ossible that LVEF recovery in some patients was blunted
nd, as a consequence, the number of responders underes-
imated due to the additional cardiotoxic effect of new
hemotherapy administered during follow-up.
onclusions
n cancer patients treated with AC, the clinical benefit of
ncologic treatment may be thwarted by the development of
C-CMP. Our study clearly indicates, however, that a
omplete LVEF recovery and associated cardiac events
eduction may be achieved when cardiac dysfunction is
etected early and a treatment with ACEI, possibly in
ombination with beta-blockers, is promptly initiated.
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